← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (76)Meta-analysis (20)Treatment guideline (4)Phase 3 study (24)Randomized trial (14)Systematic review (14)Clinical trial (680)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis. (2024/12/01) ♡
• Uptake of guideline-based testing for chronic viral hepatitis in Australian primary care: retrospective analysis of electronic medical record data. (2024/12/01) ♡
• Potential Role of the Tie2/ Angiopoietin System in Hepatitis C Virus- Induced Hepatocellular Carcinoma. (2024/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical Advantages of Phlebotomy: An Umbrella Review of Meta-Analyses. (2024/12/01) ♡
• Prevalence and risk factors of liver fibrosis in patients with metabolic-associated fatty liver disease undergoing bariatric surgery. (2024/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes. (2024/11/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review. (2024/11/28) ♡
• Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients. (2024/11/28) ♡
• Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C. (2024/11/26) ♡
• Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China. (2024/11/26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil. (2024/11/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management. (2024/11/24) ♡
• Different dynamics of soluble inflammatory mediators after clearance of respiratory SARS-CoV-2 versus blood-borne hepatitis C virus infections. (2024/11/22) ♡
• Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals. (2024/11/15) ♡
• Liver Dysfunction in Hyperthyroidism. (2024/11/08) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cholangiolocellular Carcinoma Misdiagnosed As Hemangioma: Unique Central Fibrotic Area Devoid of Cancer Cells Detected on a Seven-Year Follow-Up. (2024/11/05) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis. (2024/11/04) ♡
• Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease. (2024/11/01) ♡
• High frequency of anti-Saccharomyces cerevisiae antibodies in chronic hepatitis C. (2024/11/01) ♡
• Accelerated Phenotypic Aging Associated With Hepatitis C Infection: Results From the U.S. National Health and Nutrition Examination Surveys 2015-2018. (2024/11/01) ♡
• Perceived patient navigator services and characteristics to address barriers to linkage to hepatitis C care among people released from provincial prison in Quebec, Canada. (2024/11/01) ♡
• Long-term Effect of the HCV Elimination With Direct-acting Antivirals on the Progression of Gastroesophageal Varices. (2024/11/01) ♡
• Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans. (2024/11/01) ♡
• Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting. (2024/10/31) ♡
• Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs). (2024/10/30) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Roseoside Is a Bioactive Compound in Kirengeshoma koreana Nakai Extract with Potent In Vitro Antiviral Activity Against Hepatitis C Virus. (2024/10/30) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The value of serum Mac-2 binding protein glycosylation isomer in the diagnosis of liver fibrosis: a systematic review and meta-analysis. (2024/10/30) ♡
• Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy. (2024/10/26) ♡
• Assessing the Efficacy of Novel Antiviral Therapies in Treating Hepatitis C. (2024/10/24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination. (2024/10/23) ♡
• Recurrent fungal endocarditis of the aortic valve: A challenging clinical scenario. (2024/10/23) ♡
• Association of IL-6 G-174C (rs1800795) variant with the susceptibility to hepatocellular carcinoma in patients with chronic hepatitis. (2024/10/21) ♡
• HCV genotype distribution in Istanbul: A detailed 7 year epidemiological overview and impact of Covid-19 pandemic. (2024/10/21) ♡
• Benchmarking of an Intervention Aiming at the Micro-Elimination of Hepatitis C in Vulnerable Populations in Perpignan, France, to Inform Scale-Up and Elimination on the French Territory. (2024/10/21) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Mechanism of APOBEC3B in Hepatitis B Virus Infection and HBV Related Hepatocellular Carcinoma Progression, Therapeutic and Prognostic Potential. (2024/10/17) ♡
• Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study. (2024/10/16) ♡
• Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard? (2024/10/10) ♡
• Clinical audit of quality of care among patients with viral hepatitis in primary care in a low endemic region. (2024/10/08) ♡
• Association of nuclear factor-kappa B1 (NF-κB1) Ins/Del gene polymorphism with Hepatitis C virus outcomes. (2024/10/01) ♡
• Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients. (2024/10/01) ♡
• Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation. (2024/09/30) ♡
• Transient elastography and diffusion-weighted magnetic resonance imaging for assessment of liver fibrosis in children with chronic hepatitis C. (2024/09/25) ♡
• Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. (2024/09/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Idiopathic Mixed Cryoglobulinemia: A Diagnostic Challenge. (2024/09/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection. (2024/09/17) ♡
• Necrolytic Acral Erythema. (2024/09/11) ♡
• The State of Hepatitis C Elimination from the Front Lines: A Qualitative Study of Provider-Perceived Gaps to Treatment Initiation. (2024/09/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain. (2024/09/01) ♡
• Prediction of Hepatocellular Carcinoma in a Portuguese Population after Hepatitis C Cure: Comparative Accuracy of Noninvasive Tests (Transient Elastography, FIB-4, and aMAP). (2024/08/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A case presentation of widespread macular amyloidosis associated with dual hepatitis B and hepatitis C infection. (2024/08/15) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.